This Article Full Text Full Text (PDF) All Versions of this Article: 34/10/2333    most recent 01.STR.0000091397.81767.40v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by PROGRESS Search for Related Content PubMed PubMed Citation Articles by PROGRESS, Related Collections Cerebrovascular disease/stroke Clinical Studies Primary and Secondary Stroke Prevention Other Stroke Treatment - Medical Transient Ischemic Attacks

(Stroke. 2003;34:2333.)
© 2003 American Heart Association, Inc.

Original Contributions

Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease

A Randomized Controlled Trial

A list of the members of the PROGRESS Collaborative Group and their affiliations appears in the Appendix.

Correspondence to Dr John Chalmers, Institute for International Health, University of Sydney, PO Box 576, Newtown, Sydney, New South Wales 2042, Australia. E-mail chalmers{at}iih.usyd.edu.au

Background and Purpose— We sought to quantify the effects of blood pressure lowering on long-term disability and dependency among patients with cerebrovascular disease.

Methods— We performed a randomized, double-blind, placebo-controlled trial. A total of 6105 participants with a history of stroke or transient ischemic attack in the past 5 years were recruited from 172 hospital outpatient clinics in 10 countries. Subjects were randomly assigned to the following groups: active treatment (angiotensin-converting enzyme inhibitor perindopril [4 mg/d] for all patients, with the diuretic indapamide added at the discretion of treating physicians) or matching placebo(s). Measurements were disability (defined as a Barthel Index score 99/100) and dependency (a positive response to the following question: "In the last 2 weeks has the patient required regular help with everyday activities?").

Results— The median duration of follow-up was 4 years. At the last available assessment, 19% of the active treatment group and 22% of the placebo group were disabled (adjusted odds ratio, 0.76; 95% CI, 0.65 to 0.89; P<0.001). Twelve percent of the active treatment group and 14% of the placebo group were dependent (adjusted odds ratio, 0.84; 95% CI, 0.71 to 0.99; P=0.04). The effects of treatment appeared to be mediated primarily through the prevention of disability and dependency associated with recurrent stroke. Four-year treatment with the study drug regimen would be expected to result in the avoidance of 1 case of long-term disability for every 30 (95% CI, 19 to 79) patients.

Conclusions— Among individuals with cerebrovascular disease, a perindopril-based blood pressure–lowering regimen not only reduced the risk of stroke and major vascular events but also substantially reduced the risks of associated long-term disability and dependency.

Key Words: antihypertensive therapy • indapamide • perindopril • stroke, hemorrhagic • stroke, ischemic

This article has been cited by other articles:

				I. M. Hajjar, M. Keown, P. Lewis, and A. Almor Angiotensin Converting Enzyme Inhibitors and Cognitive and Functional Decline in Patients with Alzheimer's Disease: An Observational Study American Journal of Alzheimer's Disease and Other Dementias, March 1, 2008; 23(1): 77 - 83. [Abstract] [PDF]

				A. Viswanathan, A. Gschwendtner, J. -P. Guichard, F. Buffon, R. Cumurciuc, M. O'Sullivan, M. Holtmannspotter, C. Pachai, M. -G. Bousser, M. Dichgans, et al. Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL Neurology, July 10, 2007; 69(2): 172 - 179. [Abstract] [Full Text] [PDF]

				P. G. Surtees, N. W.J. Wainwright, R. L. Luben, N. J. Wareham, S. A. Bingham, and K.-T. Khaw Adaptation to Social Adversity Is Associated With Stroke Incidence: Evidence From the EPIC-Norfolk Prospective Cohort Study Stroke, May 1, 2007; 38(5): 1447 - 1453. [Abstract] [Full Text] [PDF]

				D. J. Campbell, M. Woodward, J. P. Chalmers, S. A. Colman, A. J. Jenkins, B. E. Kemp, B. C. Neal, A. Patel, and S. W. MacMahon Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Pro-B-Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease Arch Neurol, January 1, 2006; 63(1): 60 - 65. [Abstract] [Full Text] [PDF]

				C. S. Carter, G. Onder, S. B. Kritchevsky, and M. Pahor Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1437 - 1446. [Abstract] [Full Text] [PDF]

				A. Patel, M. Woodward, D. J. Campbell, D. R. Sullivan, S. Colman, J. Chalmers, B. Neal, and S. MacMahon Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease Eur. Heart J., September 2, 2005; 26(18): 1910 - 1915. [Abstract] [Full Text] [PDF]

				R. Wennberg and C. Zimmermann The PROGRESS trial three years later: time for a balanced report of effectiveness BMJ, October 23, 2004; 329(7472): 968 - 970. [Full Text] [PDF]

				S. MacMahon, B. Neal, A. Rodgers, and J. Chalmers The PROGRESS trial three years later: time for more action, less distraction BMJ, October 23, 2004; 329(7472): 970 - 971. [Full Text] [PDF]

				M. Fisher and A. Davalos Emerging Therapies for Cerebrovascular Disorders Stroke, February 1, 2004; 35(2): 367 - 369. [Full Text] [PDF]